Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, Lubitz J, Hellerhoff K, Ankel C, Graßhoff ST, Deuschle P, Hanf V, Belke K, Dall P, Dorn J, Kaltenecker G, Kuehn T, Beckmann U, Potenberg J, Blohmer JU, Kostara A, Breit E, Holtschmidt J, Traut E, Reinisch M. Kuemmel S, et al. Among authors: harrach h. Ann Surg. 2022 Nov 1;276(5):e553-e562. doi: 10.1097/SLA.0000000000004572. Epub 2020 Nov 4. Ann Surg. 2022. PMID: 33156057
[No title available]
[No authors listed] [No authors listed] PMID: 33579947
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response.
Bruzas S, Gluz O, Harbeck N, Schmid P, Cortés J, Blohmer J, Seiberling C, Chiari O, Harrach H, Ataseven B, Shenoy S, Dyson MH, Traut E, Theuerkauf I, Gebauer D, Kuemmel S, Reinisch M. Bruzas S, et al. Among authors: harrach h. NPJ Breast Cancer. 2022 Mar 29;8(1):42. doi: 10.1038/s41523-022-00403-3. NPJ Breast Cancer. 2022. PMID: 35351903 Free PMC article.
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy.
Reinisch M, Bruzas S, Gluz O, Ataseven B, Schmid P, Cortés J, Blohmer JU, Shenoy S, Dyson MH, Dittmer-Grabowski C, Chiari O, Harrach H, Gebauer D, Traut A, Kuemmel S. Reinisch M, et al. Among authors: harrach h. Mol Oncol. 2023 Jun;17(6):1060-1075. doi: 10.1002/1878-0261.13435. Epub 2023 Apr 24. Mol Oncol. 2023. PMID: 37057719 Free PMC article.
Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
Kuemmel S, Heil J, Bruzas S, Breit E, Schindowski D, Harrach H, Chiari O, Hellerhoff K, Bensmann E, Hanf V, Graßhoff ST, Deuschle P, Belke K, Polata S, Paepke S, Warm M, Meiler J, Schindlbeck C, Ruhwedel W, Beckmann U, Groh U, Dall P, Blohmer JU, Traut A, Reinisch M. Kuemmel S, et al. Among authors: harrach h. JAMA Surg. 2023 Aug 1;158(8):807-815. doi: 10.1001/jamasurg.2023.1772. JAMA Surg. 2023. PMID: 37285140
Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany.
Reinisch M, Bruzas S, Spoenlein J, Shenoy S, Traut A, Harrach H, Chiari O, Cremer E, Ataseven B, Gubelt L, Kuemmel S. Reinisch M, et al. Among authors: harrach h. Ther Adv Med Oncol. 2023 Sep 28;15:17588359231200454. doi: 10.1177/17588359231200454. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37789989 Free PMC article.
11 results